A new era of weight management is on the horizon. In this episode of The Scalpel’s Edge, learn how oral GLP-1 medications like semaglutide (Rebelsus) are changing the landscape of obesity care and cardiovascular health. Explore key findings from the OASIS-4 Phase 3 trial, new FDA updates, and what the data reveals about blood sugar control, heart health, and weight reduction across all age groups. Discover why oral options may soon rival injectables like Ozempic, Wegovy, and Mounjaro—and what this means for the millions of people seeking sustainable wellness solutions.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD